medigraphic.com
ISSN 1405-1710 (Print)

2022, Number 1-2

<< Back Next >>

Rev Cent Dermatol Pascua 2022; 31 (1-2)

Chronic inducible urticarias. Classification and general characteristics

Cardona-Hernández MÁ, Candelaria CPL

Language: Spanish
References: 79
Page: 16-25
PDF size: 388.73 Kb.


ABSTRACT

Chronic inducible urticarias are a group of inflammatory dermatoses characterized by recurrence of itchy wheals and/or angioedema lasting more than six weeks, and induced by specific physical or environmental trigger (cold, heat, pressure, sunlight, vibration). The following review focuses on physical and non-physical chronic urticarias, we discuss the clinical characteristics, the diagnostic approach, including provocation and threshold tests, as well as the available treatment options.


REFERENCES

  1. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018; 73: 1393-1414. doi: 10.1111/all.13397.

  2. Radonjic-Hoesli S, Hofmeier KS, Micaletto S, Schmid-Grendelmeier P, Bircher A, Simon D. Urticaria and angioedema: an update on classification and pathogenesis. Clin Rev Allergy Immunol. 2018; 54: 88-101. doi: 10.1007/s12016-017-8628-1.

  3. Antia C, Baquerizo K, Korman A, Bernstein JA, Alikhan A. Urticaria: a comprehensive review: epidemiology, diagnosis, and work-up. J Am Acad Dermatol. 2018; 79: 599-614. doi: 10.1016/j.jaad.2018.01.020.

  4. Westby EP, Lynde C, Sussman G. Chronic urticaria: following practice guidelines. Skin Therapy Lett. 2018; 23: 1-4.

  5. Dabija D, Tadi P. Chronic urticaria. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.

  6. Saini SS, Kaplan AP. Chronic spontaneous urticaria: the devil's itch. J Allergy Clin Immunol Pract. 2018; 6: 1097-1106. doi: 10.1016/j.jaip.2018.04.013.

  7. Pozderac I, Lugovic-Mihic L, Artukovic M, Stipic-Markovic A, Kuna M, Fercek I. Chronic inducible urticaria: classification and prominent features of physical and non-physical types. Acta Dermatovenerol Alp Pannonica Adriat. 2020; 29: 141-148.

  8. Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract. 2018; 6: 1119-1130. doi: 10.1016/j.jaip.2018.03.007.

  9. Sánchez-Borges M, González-Aveledo L, Caballero-Fonseca F, Capriles-Hulett A. Review of physical urticarias and testing methods. Curr Allergy Asthma Rep. 2017; 17: 51.

  10. Curto-Barredo L, Pujol RM, Roura-Vives G, Gimenez-Arnau AM. Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response. Eur J Dermatol. 2019; 29: 627-635.

  11. Church MK, Kolkhir P, Metz M, Maurer M. The role and relevance of mast cells in urticaria. Immunol Rev. 2018; 282: 232-247.

  12. Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017; 139: 1772-1781.e1.

  13. Maurer M, Schütz A, Weller K, Schoepke N, Peveling-Oberhag A, Staubach P et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017; 140: 870-873.e5.

  14. Metz M, Schütz A, Weller K, Gorczyza M, Zimmer S, Staubach P et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017; 140: 864-867.e5.

  15. Grimm V, Mempel M, Ring J, Abeck D. Congenital symptomatic dermographism as the first symptom of mastocytosis. Br J Dermatol. 2000; 143: 1109.

  16. Siebenhaar F, Weller K, Mlynek A, Magerl M, Altrichter S, Vieira Dos Santos R et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol. 2007; 32: 241-245.

  17. Keahey TM, Indrisano J, Kaliner MA. A case study on the induction of clinical tolerance in cold urticaria. J Allergy Clin Immunol. 1988; 82: 256-261.

  18. Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018; 141: 638-649.

  19. Darling M, Lambiase MC, Hodson DS. Localized heat induced urticaria: report of a case. J Drugs Dermatol. 2004; 3: 75-76.

  20. Dice JP, Gonzalez-Reyes E. Physical (inducible) forms of urticaria. [Updated 2019 Dec 12]. Available in: www.uptodate.com/contents/physical-inducibleforms-of-urticaria

  21. Komarow HD, Arceo S, Young M, Nelson C, Metcalfe DD. Dissociation between history and challenge in patients with physical urticaria. J Allergy Clin Immunol Pract. 2014; 2: 786-790.

  22. Schoepke N, Abajian M, Church MK, Magerl M. Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism. Clin Exp Dermatol. 2015; 40: 399-403.

  23. Nobles T, Muse ME, Schmieder GJ. Dermatographism. [Updated 2022 Feb 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available in: https://www.ncbi.nlm.nih.gov/books/NBK531496/

  24. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014; 133: 1270-1277.

  25. Mlynek A, Vieira dos Santos R, Ardelean E, Weller K, Magerl M, Church MK et al. A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clin Exp Dermatol. 2013; 38: 360-366; quiz 366.

  26. Beck LA, Bernstein JA, Maurer M. A review of international recommendations for the diagnosis and management of chronic urticaria. Acta Derm Venereol. 2017; 97: 149-158. doi: 10.2340/00015555-2496.

  27. Golberg O, Johnston GA, Wilkinson M. Symptomatic dermographism mimicking latex allergy. Dermatitis. 2014; 25: 101-103.

  28. Le M, Miedzybrodzki B, Olynych T, Chapdelaine H, Ben-Shoshan M. Natural history and treatment of cutaneous and systemic mastocytosis. Postgrad Med. 2017; 129: 896-901.

  29. Abajian M, Schoepke N, Altrichter S, Zuberbier T, Maurer M. Physical urticarias and cholinergic urticaria. Immunol Allergy Clin N Am. 2014; 34: 73-88. doi: 10.1016/j.iac.2013.09.010.

  30. da Silva DM, Vieira TM, Pereira AM, de Sousa Moreira AM, Delgado JL. Cross-reactive LTP sensitization in food-dependent exercise-induced urticaria/anaphylaxis: a pilot study of a component-resolved and in vitro depletion approach. Clin Transl Allergy. 2016; 6: 46.

  31. Lawlor F, Black AK. Delayed pressure urticaria. Immunol Allergy Clin North Am. 2004; 24: 247-258.

  32. Alangari AA, Twarog FJ, Shih MC, Schneider LC. Clinical features and anaphylaxis in children with cold urticaria. Pediatrics. 2004; 113: e313-e317.

  33. Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016; 71: 780-802. doi: 10.1111/all.12884.

  34. Martinez-Escala ME, Curto-Barredo L, Carnero L, Pujol RM, Giménez-Arnau AM. Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one-year study. Acta Derm Venereol. 2015; 95: 278-282. doi: 10.2340/00015555-1918.

  35. Magerl M, Abajian M, Krause K, Altrichter S, Siebenhaar F, Church MK. An improved Peltier effect-based instrument for critical temperature threshold measurement in cold- and heat-induced urticaria. J Eur Acad Dermatol Venereol. 2015; 29: 2043-2045.

  36. Siebenhaar F, Staubach P, Metz M, Magerl M, Jung J, Maurer M. Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria. J Allergy Clin Immunol. 2004; 114: 1224-1225.

  37. Magerl M, Schmolke J, Siebenhaar F, Zuberbier T, Metz M, Maurer M. Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy. 2007; 62: 1465-1468.

  38. Bullerkotte U, Wieczorek D, Kapp A, Wedi B. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy. 2010; 65: 931-932.

  39. Masuoka E, Fukunaga A, Kishigami K, Jimbo H, Nishioka M, Uchimura Y et al. Successful and long-lasting treatment of solar urticaria with ultraviolet A rush hardening therapy. Br J Dermatol. 2012; 167: 198-201.

  40. Pressler A, Grosber M, Halle M, Ring J, Brockow K. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema. Clin Exp Dermatol. 2013; 38: 151-153.

  41. Kalathoor I. Snoring-induced vibratory angioedema. Am J Case Rep. 2015; 16: 700-702. doi: 10.12659/AJCR.894636.

  42. Aloyouny A, Stoopler ET. Vibrational angioedema: considerations for oral health care providers. Spec Care Dentist. 2016; 36: 335-338. doi: 10.1111/scd.12185.

  43. Kulthanan K, Ungprasert P, Tapechum S, Rujitharanawong C, Kiratiwongwan R, Munprom K et al. Vibratory angioedema subgroups, features, and treatment: results of a systematic review. J Allergy Clin Immunol Pract. 2021; 9: 971-984. doi: 10.1016/j.jaip.2020.09.009.

  44. Fukunaga A, Washio K, Hatakeyama M, Oda Y, Ogura K, Horikawa T et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management. Clin Auton Res. 2018; 28: 103-113.

  45. Vadas P, Sinilaite A, Chaim M. Cholinergic urticaria with anaphylaxis: an underrecognized clinical entity. J Allergy Clin Immunol Pract. 2016; 4: 284-291.

  46. Pitarch G, Torrijos A, Martínez-Menchón T, Sánchez-Carazo JL, Fortea JM. Familial aquagenic urticaria and Bernard-Soulier syndrome. Dermatology. 2006; 212: 96-97.

  47. Seize MB, Ianhez M, de Souza PK, Rotta O, Cestari Sda C. Familial aquagenic urticaria: report of two cases and literature review. An Bras Dermatol. 2009; 84: 530-533.

  48. Zhai H, Zheng Y, Fautz R, Fuchs A, Maibach HI. Reactions of non-immunologic contact urticaria on scalp, face, and back. Skin Res Technol. 2012; 18: 436-441.

  49. Adisesh A, Robinson E, Nicholson PJ, Sen D, Wilkinson M; Standards of Care Working Group. U.K. standards of care for occupational contact dermatitis and occupational contact urticaria. Br J Dermatol. 2013; 168: 1167-1175.

  50. Bensefa-Colas L, Telle-Lamberton M, Faye S, Bourrain JL, Crépy MN, Lasfargues G et al. Occupational contact urticaria: lessons from the French National Network for Occupational Disease Vigilance and Prevention (RNV3P). Br J Dermatol. 2015; 173: 1453-1461.

  51. Magerl M, Schmolke J, Metz M, Zuberbier T, Siebenhaar F, Maurer M. Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clin Exp Dermatol. 2009; 34: e137-e140.

  52. Dressler C, Werner RN, Eisert L, Zuberbier T, Nast A, Maurer M. Chronic inducible urticaria: A systematic review of treatment options. J Allergy Clin Immunol. 2018; 141: 1726-1734. doi: 10.1016/j.jaci.2018.01.031.

  53. Schaefer P. Acute and chronic urticaria: evaluation and treatment. Am Fam Physician. 2017; 95: 717-724.

  54. van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol. 2002; 146: 110-113.

  55. Krause K, Ardelean E, Kessler B, Magerl M, Metz M, Siebenhaar F et al. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy. 2010; 65: 1494-1495.

  56. Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy. 2010; 65: 138-139.

  57. Rodríguez-Rodríguez M, Antolin-Amerigo D, Barbarroja-Escudero J, Sánchez-González MJ, Alvarez-Mon M. Successful treatment of severe delayed pressure angio-oedema with omalizumab. Allergol Immunopathol (Madr). 2014; 42: 78-80.

  58. Maurer M, Hawro T, Krause K, Magerl M, Metz M, Siebenhaar F et al. Diagnosis and treatment of chronic inducible urticaria. Allergy. 2019; 74: 2550-2553.

  59. Brodská P, Schmid-Grendelmeier P. Treatment of severe cold contact urticaria with omalizumab: case reports. Case Rep Dermatol. 2012; 4: 275-280.

  60. Kring Tannert L, Stahl Skov P, Bjerremann Jensen L, Maurer M, Bindslev-Jensen C. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. Dermatology. 2012; 224: 101-105.

  61. Carballada F, Nuñez R, Martin-Lazaro J, Juárez Y, Castiñeira I, Carballada F et al. Omalizumab treatment in 2 cases of refractory heat urticaria. J Investig Allergol Clin Immunol. 2013; 23: 519-521.

  62. Baliu-Piqué C, Aguilera Peiró P. Three cases of solar urticaria successfully treated with omalizumab. J Eur Acad Dermatol Venereol. 2016; 30: 704-706.

  63. Mathelier-Fusade P, Vermeulen C, Leynadier F. Vibratory angioedema. Ann Dermatol Venereol. 2001; 128: 750-752.

  64. Boyden SE, Desai A, Cruse G, Young ML, Bolan HC, Scott LM et al. Vibratory urticaria associated with a missense variant in ADGRE2. N Engl J Med. 2016; 374: 656-663. doi: 10.1056/NEJMoa1500611.

  65. Pezzolo E, Peroni A, Gisondi P, Girolomoni G. Heat urticaria: a revision of published cases with an update on classification and management. Br J Dermatol. 2016; 175: 473-478.

  66. Borzova E, Rutherford A, Konstantinou GN, Leslie KS, Grattan CE. Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study. J Am Acad Dermatol. 2008; 59: 752-757.

  67. Magerl M, Philipp S, Manasterski M, Friedrich M, Maurer M. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol. 2007; 119: 752-754.

  68. Eskeland S, Tanum L, Halvorsen JA. Delayed pressure urticaria treated with the selective serotonin reuptake inhibitor escitalopram. Clin Exp Dermatol. 2016; 41: 526-528.

  69. Swerlick RA, Puar N. Delayed pressure urticaria: response to treatment with sulfasalazine in a case series of seventeen patients. Dermatol Ther. 2015; 28: 318-322.

  70. Grundmann SA, Kiefer S, Luger TA, Brehler R. Delayed pressure urticaria - dapsone heading for first-line therapy? J Dtsch Dermatol Ges. 2011; 9: 908-912.

  71. Kalogeromitros D, Kempuraj D, Katsarou-Katsari A, Gregoriou S, Makris M, Boucher W et al. Theophylline as "add-on" therapy in patients with delayed pressure urticaria: a prospective self-controlled study. Int J Immunopathol Pharmacol. 2005; 18: 595-602.

  72. Metz M, Scholz E, Ferran M, Izquierdo I, Gimenez-Arnau A, Maurer M. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol. 2010; 104: 86-92.

  73. Weinstein ME, Wolff AH, Bielory L. Efficacy and tolerability of second- and third-generation antihistamines in the treatment of acquired cold urticaria: a meta-analysis. Ann Allergy Asthma Immunol. 2010; 104: 518-522.

  74. Abajian M, Curto-Barredo L, Krause K, Santamaria E, Izquierdo I, Church MK et al. Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria. Acta Derm Venereol. 2016; 96: 56-59.

  75. Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011; 154: 177-180.

  76. Gualdi G, Monari P, Rossi MT, Crotti S, Calzavara-Pinton PG. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis. Br J Dermatol. 2012; 166: 1373-1374.

  77. Du-Thanh A, Debu A, Lalheve P, Guillot B, Dereure O, Peyron JL. Solar urticaria: a time-extended retrospective series of 61 patients and review of literature. Eur J Dermatol. 2013; 23: 202-207.

  78. Wolf R, Herzinger T, Grahovac M, Prinz JC. Solar urticaria: long-term rush hardening by inhibition spectrum narrow-band UVB 311 nm. Clin Exp Dermatol. 2013; 38: 446-447.

  79. Aubin F, Porcher R, Jeanmougin M, Léonard F, Bedane C, Moreau A et al. Severe and refractory solar urticaria treated with intravenous immunoglobulins: a phase II multicenter study. J Am Acad Dermatol. 2014; 71: 948-953.e1.




2020     |     www.medigraphic.com